Anlotinib is a novel multi-target small molecule tyrosine kinase inhibitor (TKI), which exerts an inhibitory effect against angiogenesis and tumor growth by blocking vascular endothelial growth factor receptor(VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and c-Kit. This evidence concerns the gene KDR and neoplasm.